AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2013
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/cdee93bca07145d3b4ee0e020e486f40 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|